Marshall Wace North America’s Cytokinetics CYTK Stock Holding History

Marshall Wace North America’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$1.65M	Sell	46,260 -1,100,242	-96%	-$32.4M	0.01%	778
2021 Q2	$22.7M	Sell	1,146,502 -1,553,621	-58%	-$36.5M	0.09%	229
2021 Q1	$62.8M	Buy	2,700,123 +632,255	+31%	+$13.5M	0.26%	86
2020 Q4	$43M	Buy	+2,067,868	New	+$37.8M	0.19%	132
2018 Q4	–	Sell	-131,062	Closed	-$1.29M	–	1504
2018 Q3	$1.29M	Buy	+131,062	New	+$1.05M	0.01%	567

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Marshall Wace North America's CYTK Position: Q3 2021 in Review

Marshall Wace North America reduced its Cytokinetics (CYTK) stake by 96% in Q3 2021, selling an estimated $32.4M and leaving 46,260 shares worth $1.65M. The position accounts for 0.01% of the portfolio, ranked #778.

Marshall Wace North America first reported a position in CYTK in Q3 2018 and has held it in 5 quarters since. The position peaked at $62.8M in Q1 2021. 211 funds tracked by Wall St. Rank hold CYTK as of Q3 2021.

Marshall Wace North America held 46,260 shares of Cytokinetics worth $1.65M as of Q3 2021.
Marshall Wace North America sold 1,100,242 Cytokinetics shares in Q3 2021, an estimated $32.4M.
Cytokinetics made up 0.01% of Marshall Wace North America's portfolio in Q3 2021, its #778 holding.
Marshall Wace North America first reported a position in Cytokinetics in Q3 2018 and has held it in 5 quarters since.
Marshall Wace North America's Cytokinetics position peaked at $62.8M in Q1 2021.
211 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.